Cannabis Science (CBIS) 10-Q/A 24 Nov 15 2015 Q3 Quarterly report (amended) Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 20, 2015
Document And Entity Information
Entity Registrant Name	CANNABIS SCIENCE, INC.
Entity Central Index Key	1,024,626
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding	1,287,155,296	1,416,655,296
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,015

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current Assets
Cash	$ 4,791	$ 10,061
Inventory	18,476
Other receivables	3,072	$ 8,670
Prepaid expenses and deposits	88,588	97,626
Loans receivable, related party	22,936	50,000
Total current assets	137,863	166,357
Deposits (Note 8)	971,500	$ 971,500
Goodwill	280,141
Equity method investee (Note 9)	156,181	$ 243,969
TOTAL ASSETS	1,545,685	1,381,826
Current Liabilities
Accounts payable	127,440	153,094
Accrued expenses, primary management fees (Note 5)	2,029,807	$ 1,716,807
Dividends payable	473,527
Advances from related parties (Note 5)	756,993	$ 203,892
Management bonuses	300,000	300,000
Notes payable to stockholders (Note 6)	1,466,513	1,581,486
Total current liabilities and total liabilities	5,154,280	3,955,279
Stockholders' Deficit
Series A Preferred Stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at September 30,2015 and December 31, 2014	1,000	1,000
Common stock, $.001 par value, 3,000,000,000 and 1,500,000,000 shares authorized as of September 30, 2015 and December 31, 2014; 1,287,155,296 issued and outstanding as of September 30,2015 and 1,032,123,906 at December 31, 2014, Common stock, Class A, $.001 par value, 100,000,000 shares authorized, none issued and outstanding as of September 30, 2015 and December 31, 2014	1,287,155	1,032,124
Prepaid consulting	5,476,985	4,448,696
Additional paid-in-capital, including 104,000,000 shares pending to be issued	125,519,240	$ 110,256,424
Common stock receivable	615,000
Accumulated deficit	(123,991,168)	$ (109,393,306)
Cumulative exchange translation	(100,248)	(20,999)
Equity attributable to common shareholders	(3,376,006)	$ (2,573,453)
Non-controlling interest	(232,589)
Total stockholders' deficit	(3,608,595)	$ (2,573,453)
TOTAL LIABILTIES AND STOCKHOLDERS' DEFICIT	1,545,685	1,381,826
Series A Preferred Stock [Member]
Stockholders' Deficit
Series A Preferred Stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at September 30,2015 and December 31, 2014	1,000	1,000
Equity attributable to common shareholders	1,000	1,000
Total stockholders' deficit	1,000	1,000
TOTAL LIABILTIES AND STOCKHOLDERS' DEFICIT	$ 1,000	$ 1,000
Common Class A [Member]
Stockholders' Deficit
Common stock, $.001 par value, 3,000,000,000 and 1,500,000,000 shares authorized as of September 30, 2015 and December 31, 2014; 1,287,155,296 issued and outstanding as of September 30,2015 and 1,032,123,906 at December 31, 2014, Common stock, Class A, $.001 par value, 100,000,000 shares authorized, none issued and outstanding as of September 30, 2015 and December 31, 2014
Equity attributable to common shareholders
Total stockholders' deficit
TOTAL LIABILTIES AND STOCKHOLDERS' DEFICIT

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	3,000,000,000	1,500,000,000
Common stock, shares issued	1,287,155,296	1,032,123,906
Common stock, shares outstanding	1,287,155,296	1,032,123,906
Additional paid in-capital pending shares to be issued	104,000,000
Series A Preferred Stock [Member]
Preferred stock, par value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	1,000,000	1,000,000
Preferred stock, shares outstanding	1,000,000	1,000,000
Common Class A [Member]
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued
Common stock, shares outstanding

Consolidated Statements Of Oper

Consolidated Statements Of Operations And Other Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Revenue	$ 4,150		$ 4,150	$ 1,031
Cost of Goods Sold	2,088		$ 2,088
Operating Expenses
Investor relations	(10,500)
Professional Fees	22,424	$ 29,277	$ 626,132	$ 71,622
Net loss on settlement of liabilites	$ (770,000)		$ (4,488,076)	(2,116,500)
Depreciation and Amortization		$ 16,122		54,373
Research and Development	$ 68,552	11,847	$ 381,772	11,847
General and administrative	2,967,024	597,077	8,710,982	4,845,803
Total operating expenses	3,817,500	654,323	14,206,962	7,100,145
Net Operating Loss	(3,815,438)	$ (654,323)	(14,204,900)	(7,099,114)
Other income (expense)
Interest expense, net	$ 603		603	$ 65
Impairment of goodwill			$ 64,421
Debt refinance costs				$ 833,000
Warrant expense				97,894
Unrealized gain (loss) on marketable common stock	$ (79,500)	$ (21,000)	$ (87,000)	(36,000)
Total other income (expense)	(80,103)	(21,000)	(152,024)	(966,959)
Net Loss	(3,895,541)	$ (675,323)	(14,356,924)	$ (8,066,073)
Less: Net loss attributable to non-controlling interest	(177,621)		(232,589)
Net loss attributable to common shareholders	(3,717,920)	$ (675,323)	(14,124,335)	$ (8,066,073)
Other Comprehensive Income
Foreign exchange translation adjustment	(49,708)	(16,690)	(79,249)	(17,641)
Total other comprehensive income (loss)	(49,708)	(16,690)	(79,249)	(17,641)
Comprehensive loss attributable to Cannabis Science, Inc.	$ (3,767,628)	$ (692,013)	$ (14,203,584)	$ (8,083,714)
Net loss per common share: Basic and diluted	$ 0	$ 0	$ (0.01)	$ (0.01)
Weighted average number of common shares outstanding	1,285,416,166	836,783,906	1,213,795,570	778,287,313

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (14,356,924)	$ (8,066,073)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		54,373
Stock issued for services	$ 8,585,654	4,366,539
Stock issued for the extension of debt		833,000
Warrant expense		97,894
Foreign exchange adjustment	$ (79,249)	(17,641)
Loss on settlement of liabilities	$ (4,488,076)	(2,116,500)
Loss on marketable securities		$ (36,000)
Equity investee, Endocan Corporation	$ (87,788)
Changes in operating assets and liabilities:
Accounts receivable	(5,883)	$ 8,351
Inventory	(1,937)
Prepaid expenses and deposits	(9,038)	$ 23,684
Accounts payable	570,893	(18,513)
Accrued expenses, including management fees	313,000	362,734
CASH FLOWS USED IN OPERATING ACTIVITES	(373,904)	$ (267,222)
CASH FLOWS FROM INVESTING ACTIVITIES
Advance receivable, related parties	(33,615)
Repayment of advances receivable, related parties	(7,351)
Cash acquired with EquiPharm	$ 6,493
Loans receivable, related parties		$ (40,596)
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES	$ 32,757	(40,596)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from advances from officer		$ 447
Proceeds from notes payable-stockholders	$ 85,877
Repayments of notes payable-stockholders		$ 250,000
Proceeds from sale of common stock	$ 250,000	1,000,000
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES	335,877	750,447
NET INCREASE (DECREASE) IN CASH	(5,270)	442,629
CASH, BEGINNING OF PERIOD	10,061	943
CASH, END OF PERIOD	4,791	443,572
SUPPLEMENTAL CASH FLOW INFORMATION:
Common stock issued for service	10,228,944	3,572,760
Common stock issued for settlement of debt	$ 4,733,904	2,146,000
Common stock issued for extension of debt		$ 833,000
Common stock issued for acquisition of EquiPharm	$ 305,000
Debt converted into common stock	245,828	$ 29,500
Accounts payable and expenses paid through note payable, stockholder	130,854	$ 13,500
Accounts payable and expenses paid through advances from related parties	466,106
Stock dividends payable	$ 473,527

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A. Organization and General Description of Business Cannabis Science, Inc. (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 7, 2009, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number. On May 7, 2009 the Company common shares commenced trading under the new stock symbol OTCBB: CBIS. Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. On February 20, 2015, the Company closed on the acquisition of additional 30.1% interest in Michigan Green Technologies LLC (“MGT”), bringing the Company’s ownership position to 50.1% controlling interest. MGT is working on various Michigan initiatives with state government to legalize and commercialize medical cannabis business, as was done in Colorado, Washington State, and other U.S. states. The Company recognized $51,367 in goodwill related to the MGT acquisition. On May 27, 2015, the Company entered into a collaborative drug development deal with IGX Bio and its GenePro®, a DNA-based immunotherapeutic that recently received FDA IND approval to enter into human trials. The companies intend to develop a joint protocol to demonstrate potential synergistic effects of their respective drug candidates in HIV, as well as potential new drug candidates. The collaboration between IGX Bio and the Company and will provide a scientific evaluation of GenePro® and CS-TATI-1 to demonstrate the enhanced potential of therapeutic vaccination and the anti-inflammatory effects of cannabinoids to deter disease progression in AIDS patients unable to control HIV replication. On May 7, 2015 the Company announced the acquisition of Equi-Pharm LLC, a USA manufacturer and distributor of specialty horse and pet grooming and topical applications. The acquisition incorporates an extensive expansion plan for Equi-Pharm including "Large Animal" such as horses, cattle, sheep and the like and "Small Animal" or "Pets" include cats, dogs, pet snakes and the like for medical and cosmetic products. B. Basis of Presentation These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S.dollars. The Company’s fiscal year end is December 31. Interim Financial Reporting While the information presented in the accompanying interim consolidated financial statements is unaudited, it includes all adjustments, which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in accordance with generally accepted accounting principles in the United States of America ("GAAP"). These interim financial statements follow the same accounting policies and methods of application as used in the December 31, 2014 audited financial statements of the Company. All adjustments are of a normal, recurring nature. Interim financial statements and the notes thereto do not contain all of the disclosures normally found in year-end audited financial statements and these Notes to Financial Statements are abbreviated and contain only certain disclosures related to the ninemonth periods ended September 30, 2015 and 2014. It is suggested that these interim financial statements be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2014 included in our Form 10-K, filed with the Securities Exchange Commission on April 21, 2015. Operating results for the ninemonths ended September 30, 2015 are not necessarily indicative of the results that can be expected for the year ending December 31, 2015. For other accounting policies please refer tothe Company’sForm 10-K with the SEC on file no. 000-28911 April 21, 2015. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2014, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. Earnings (Loss) Per Share (EPS) Basic earnings per common share are calculated by dividing net income or loss by the weighted average number of shares outstanding during the period. Diluted earnings per common share are calculated by adjusting outstanding shares, assuming conversion of all potentially dilutive stock options and warrants. The computation of diluted EPS does not assume conversion, exercise, or contingent issuance of shares that would have an anti-dilutive effect on earnings per common share. Anti-dilution results from an increase in earnings per share or reduction in loss per share from the inclusion of potentially dilutive shares in EPS calculations. Currently there are 1,700,000 stock options, which have been excluded from EPS that could potentially have a dilutive effect on EPS in the future. The table below sets forth the reconciliation for net loss and weighted average shares used for calculating basic and diluted earnings per share. Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Earnings (numerator) Net loss $ (3,767,628 ) $ (692,013 ) $ (14,203,584 ) $ (8,083,714 ) Stock dividends (473,527 ) — (473,527 ) — Net loss available to common shareholders $ (4,241,155 ) $ (692,013 ) $ (14,677,111 ) $ (8,083,714 ) Shares (denominator) Weighted average common shares outstanding 1,285,416,166 836,783,906 1,213,795,570 778,287,313 Earnings (loss) per share Basic and diluted $ (0.00 ) $ (0.00 ) $ (0.01 ) $ (0.01 )

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2015
Going Concern
Going Concern	2. GOING CONCERN The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate the continuation of the Company as a going concern. The Company reported an accumulated deficit of $123,991,168and had a stockholders’ deficit of $3,608,595 at September 30, 2015. In view of the matters described, there is substantial doubt as to the Company's ability to continue as a going concern without a significant infusion of capital. At September 30, 2015, the Company had insufficient operating revenues and cash flow to meet its financial obligations. There can be no assurance that management will be successful in implementing its plans. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company raised $250,000 through a private sale of common stock in the nine months ended September 30, 2015. Notwithstanding, we anticipate that we will have to raise additional capital to fund research and development and operations over the next 12 months. To the extent that we are required to raise additional funds to acquire research and growing facilities, and to cover costs of operations, we intend to do so through additional public or private offerings of debt or equity securities. There are no commitments or arrangements for other offerings in place, no guaranties that any such financings would be forthcoming, or as to the terms of any such financings. Any future financing may involve substantial dilution to existing investors. We had been relying on our common stock to pay third parties for services that has resulted substantial dilution to existing investors.

Fair Value Measurements And Dis

Fair Value Measurements And Disclosures	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements and Disclosures	3. FAIR VALUE MEASUREMENTS AND DISCLOSURES ASC Topic 820, Fair Value Measurement Effective January 1, 2015, the equity method investments in Endocan Corporation are measured using the more observable fair value. The decision to elect the fair value option, which is irrevocable once elected, is determined on an investment by investment basis and applied to an entire instrument. The net gains or losses on the equity investment in Endocan Corporation were recognized in unrealized gain (loss) on marketable common stock.

Business Acquisitions

Business Acquisitions	9 Months Ended
	Sep. 30, 2015
Business Acquisitions
Business Acquisitions	4. BUSINESS ACQUISITIONS The Company completed the acquisition of Equi-Pharm, LLC(“Equi-Pharm”) on May 7, 2015 by acquiring all of the issued and outstanding stock of Equi-Pharm for the sum of $305,000. The acquisition was done through stock issuance. The transaction has been accounted for using the acquisition method of accounting which requires that, among other things, assets acquired and liabilities assumed be recorded at their fair values as of the acquisition date. The Company has not finalized the determination of the fair values of the assets acquired and liabilities assumed and, therefore, the provisional amounts set forth are subject to adjustment when the valuations are completed. Under U.S. Generally Accepted Accounting Principles, companies have up to one year following an acquisition to finalize acquisition accounting. The following details the preliminary fair value of the consideration transferred to effect the acquisition of Equi-Pharm: Common stock of Cannabis Science, Inc. $ 305,000 Total fair value consideration $ 305,000 The following is a preliminary valuation of the net assets acquired by the Company in the acquisition, reconciled to the total fair value of the consideration transferred: Cash $ 6,493 Accounts receivable 285 Inventory 20,413 Accounts payable (413 ) Related party payable (1,919 ) Book value of net assets acquired as of May 7, 2015 24,859 Fair value adjustment to: Goodwill 280,141 Fair value of consideration transferred $ 305,000

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	5. RELATED PARTY TRANSACTIONS At September 30, 2015, a total of $191,344 (December 31, 2014: $191,344) in loans payable was due to Bogat Family Trust, Raymond Dabney as trustee, and $0 to Raymond Dabney (December 31, 2013: $6,166). The loan amounts due are non-interest bearing, unsecured and have no specified terms of repayment. Raymond Dabney was appointed President/CEO signed a new management agreement on November 5, 2014. At September 30, 2015, the Company owes $72,968(2014: $0) to MJR B.V. which is owned and controlled by Mario Lap director and director and officer of EU subsidiaries. The loan is unsecured, non-interest bearing, and due upon demand. On March 27, 2015, the Company’s CFO, Robert Kane, loaned Michigan Green Technologies LLC (“MGT”) $52,500 secured by a non-interest bearing promissory note due within 30 days of MGT liquidating shares in Cannabis Science, Inc. to repay the debt. The loan is unsecured, non-interest bearing, and due upon demand. As of February 20, 2015, the Company closed on its acquisition and now owns a majority 50.1% interest in MGT. At September 30, 2015, the Company held 7,500,000 common shares with a fair market value of $70,500in Endocan Corporation (“EC”) representing approximately 8.6% of the issued and outstanding shares of EC. The value of the shares at September 30, 2015 was determined to be $0.01 per share or $70,500 with the Company recording an unrealized lossof $87,000for the ninemonths ended September 30, 2015 and an unrealized loss of $36,000 for the nine months ended September 30, 2014. Robert Kane, CFO and director is also the CFO and a director of EC and Chad S. Johnson, Esq., COO, general counsel and a director is also a director and general counsel for EC. Raymond C. Dabney is a controlling shareholder of both the Company and Endocan Corporation. For the nine months ended September 30, 2015, the following related party management fees and stock-based compensation was recorded: Related Party Position Amount Raymond Dabney 1 CEO and Director $ 586,201 Dr. Richard Ogden CSO 59,342 Robert Kane CFO and Director 642,511 Chad S. Johnson, Esq. COO, General Counsel, and Director 529,812 Mario Lap Director 88,659 $ 1,906,525 1 See Note 7-Equity Transactions for details of stock issuances to director and officers for services rendered. Raymond Dabney, CEO is a controlling shareholder and Chad S. Johnson, COO/General Legal Counsel of ImmunoClin Corporation (OTC: IMCL), respectively. ImmunoClin performs laboratory services and pharmaceutical development for the Company through its wholly-owned subsidiary ImmunoClin Limited that operates a laboratory at the London Biosciences Centre. Mario Lap, a director of the Company and director and officer its European subsidiaries, is conducting various business activities of the Company in Spain under his personal name and/or his personal holding company MLS Lap BV until such time as the Company is able to establish a Spanish subsidiary to conduct its own business operations and activities, including but not limited to: operating lease for farms, asset purchases, office and equipment, personnel employment and other business and operating activities as may be required from time-to-time. The Company anticipates having the Spanish subsidiary setup in fiscal 2015 at which time Mario Lap under fiduciary duty will transfer all business operating activities, agreements, and assets to the Company. The Company has signed a research and distribution agreement withCannabis Science Research Foundation (CSRF) in which three of the board of directors is the executives of the Company

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Notes Payable	6. NOTES PAYABLE As at September 30, 2015, a total of $1,466,513(December 31, 2014: $1,581,486) of notes payable are due to stockholders that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on May 30, 2012 through February 7, 2015.All promissory notes are unsecured. $150,000 in promissory notes weredue to Richard Cowan, former director and CFO of the Company. On January 15, 2015, the Company entered into a debt settlement agreement and issued 15,000,000 shares of common stock on April 7, 2015 to settle the debt owed to Cowan. All promissory notes are unsecured. $130,855 in promissory notes is due to Stacey R. Lewis, stockholder of the Company.On August 20, 2015, the Company entered into a partial debt settlement agreement to retire $25,000 of the amount and issued 25,000,000 shares of common stock to partially settle the debt owed to Lewis. All promissory notes are unsecured. On February 20, 2015, the Company issued 30,828,080 shares of common stock pursuant to a debt settlement agreement with Intrinsic Capital Corp. to settle $30,828 in debt owing under December 31, 2013 note payable. On April 29, 2015, the Company issued 40,000,000 shares of common stock pursuant to a debt settlement agreement with Intrinsic Capital Corp. to settle $40,000 in debt owing under December 31, 2013 note payable. As of September 30, 2015, the Company is default on $1,340,156 in promissory notes due and is negotiating with the debtors to extend the due dates and/or settle the debt.

Equity Transactions

Equity Transactions	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Equity Transactions	7. EQUITY TRANSACTIONS The Company was authorized to issue 1,500,000,000 shares of common stock with a par value of $0.001 per share. These shares have full voting rights. There were 1,287,155,296 shares issued and outstanding as of September 30, 2015 with 40,000,000 shares pending to be issued as of September 30, 2015. On September 2, 2015, the Company increased the number of authorized shares of common stock from 1,500,000,000 to 3,000,000,000. The Company is also authorized to issue 100,000,000 shares of common stock, Class A with a par value of $0.001 per share. These shares have 10 votes per share. There were no shares issued and outstanding as of September 30, 2015. The Company is also authorized to issue 1,000,000 shares of Series A preferred stock, with a par value of $0.001 per share. These shares have full voting rights of 1,000 votes per share. There were 1,000,000 shares issued and outstanding as of September 30, 2015. During the nine months ended September 30, 2015, the Company issued 154,203,310 shares of common stock for service under various executive and consulting agreements. On January 15, 2015, the Company issued 15,000,000 shares of Rule 144 restricted common stock with a fair market value of $997,500 for settlement of $150,000 in liabilities for loss on settlement of $847,500. On January 15, 2015, the Company sold 10,000,000 shares of Rule 144 restricted common stock with a fair market value of $250,000. On February 20, 2015, the Company issued 30,828,080 common shares for settlement of $30,828 of stockholder debt with Intrinsic Capital Corp., for a loss on settlement of $1,510,576, from the stockholder notes payable originating on July 23, 2013 ($18,328), August 15, 2013 ($1,250), August 30, 2013 ($1,250), and September 9, 2013 ($10,000). On March 27, 2015, the Company’s CFO, Robert Kane, loaned Michigan Green Technologies LLC $52,500 secured by a non-interest bearing promissory note due within 30 days of MGT liquidating shares in Cannabis Science, Inc. to repay the debt. As of February 20, 2015, the Company closed on its acquisition and now owns a majority 50.1% interest in MGT. On April 29, 2015, the Company issued 40,000,000 common shares for settlement of $40,000 of stockholder debt with Intrinsic Capital Corp., for a loss on settlement of $1,360,000, from the stockholder notes payable originating on December 31, 2013. On May 21, 2015, the Company issued 5,000,000shares of Rule 144 restricted common stock to IGX Bio, Inc. pursuant to the joint development agreement with the Company. On July 16, 2015, the Company issued 10,000,000 shares of Rule 144 restricted common stock for the acquisition of EquiPharm. On September 2, 2015, the Company approved dividend paid in the form of common stocks and warrants. The fair value of the dividends paid were $473,527. The company approved issuance of 17,500,000 shares of common stocks as consulting fee to be issued at a later date. The company approved issuance of 25,000,000 shares of common stocks as settlement of $25,000 of debt for a loss on settlement of $770,000 to be issued at a later date. The company approved issuance of 61,500,000 shares of common stocks as stock option exercise to be issued at a later date. Stock Options: A summary of the status of the Company’s option grants as of September 30, 2015 and the changes during the period then ended is presented below: Weighted-Average Shares Exercise Price Outstanding December 31, 2014 1,700,000 $ 0.41 Granted 61,500,000 0.01 Exercised (61,500,000 ) (0.01 ) Expired — Outstanding September 30, 2015 1,700,000 $ 0.41 Options exercisable at September 30, 2015 1,700,000 $ 0.41 These options expire on the date of termination of the management agreement and services thereunder with the consultants. The weighted average fair value at date of grant for options during nine months ended September 30, 2015 was estimated using the Black-Scholes option valuation model with the following: Average expected life in years 0 Average risk-free interest rate 2 % Average volatility 106 % Dividend yield 0 % The option holders exercised its options in September 2015 through cashless exercise. These exercise resulted in a receivable from the option holders of $615,000

Deposits

Deposits	9 Months Ended
	Sep. 30, 2015
Deposits
Deposits	8. DEPOSITS On February 9, 2012, the Company signed a license agreement with Apothecary to produce several Cannabis Science Brand Formulations for the California medical cannabis market. As well, Apothecary will provide research and development facilities with full circle operations including a California laboratory facility for internal research and development, along with 16 unique genetic strains specifically generated and maintained by a cancer survivor who recognizes the importance of proper growth and breeding in addition to investing $250,000 in research and development in the first 24 months. Apothecary failed to meet several contract provisions including investing $250,000 in R&D, setting up a laboratory facility, and reporting and remitting license fees owing to the Company. On November 20, 2014, the Company signed an amendment to the license agreement. Pursuant to the amendment, the Company is acquiring all property, building, and equipment of Apothecary in exchange for 14,500,000 Rule 144 restricted stock with a fair market value of $971,500. The Company recorded an equivalent deposit for the year ended December 31, 2014 until the acquisition of assets closes, which is anticipated during fiscal 2015 once all assets are identified with supported fair market values and the transfer of land title is completed.

Equity Method Investee

Equity Method Investee	9 Months Ended
	Sep. 30, 2015
Equity Method Investee
Equity Method Investee	9. EQUITY METHOD INVESTEE On November 5, 2014, the Company accounted for its investment and loans in Endocan Corporation using the fair value method pursuant to ASC 323 – Investments – Equity Method and Joint Ventures and ASC 825 – Financial Instruments – Fair Value Option. In accordance with ASC 323, when the Company does not have a controlling financial interest in an entity but exerts significant influence over the entity’s operating and financial policies, the Company accounts for its investment in accordance with the equity method of accounting. This generally applies to cases in which the Company owns a voting or economic interest of between 20 and 50 percent. The accounting using the equity method is in conjunction with appointment of Raymond Dabney as CEO and director of the Company on November 5, 2014, in addition to Mr. Dabney being a controlling shareholder of the Company since September 2009 and a controlling shareholder of Endocan Corporation since June 2013. Therefore, the Company was deemed to have significant influence and control of Endocan Corporation. On November 5, 2014, the Company recorded $247,500 in marketable securities and $85,681 in loans to Endocan Corporation to its equity method investee account in accordance with ASC 323. Using the fair value method pursuant to ASC 825, alosson investment of $87,000on the equity method investee account was recognized for the nine months ended September 30, 2015 due to the decline in the value of Endocan marketable securities.

Commitments

Commitments	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments	10. COMMITMENTS The Company has lease commitments for its European operations under private companies MLS Lap B.V. and MJR B.V. owned and controlled by Mario Lap, director and director and officer of EU subsidiaries. Negotiations are ongoing in regards to preparing finalized agreements.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	11. SUBSEQUENT EVENTS Common shares reconciliation table: Issued and outstanding as of September 30, 2015 1,287,155,296 Pending to be issued 91,500,000 Subsequent shares issued for services 8,000,000 Subsequent shares issued for debt settlement 30,000,000 Unissued and outstanding as of November 20, 2015 1,416,655,296

Summary Of Significant Accoun17

Summary Of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Summary Of Significant Accounting Policies Policies
Organization and General Description of Business	A. Organization and General Description of Business Cannabis Science, Inc. (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 7, 2009, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number. On May 7, 2009 the Company common shares commenced trading under the new stock symbol OTCBB: CBIS. Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. On February 20, 2015, the Company closed on the acquisition of additional 30.1% interest in Michigan Green Technologies LLC (“MGT”), bringing the Company’s ownership position to 50.1% controlling interest. MGT is working on various Michigan initiatives with state government to legalize and commercialize medical cannabis business, as was done in Colorado, Washington State, and other U.S. states. The Company recognized $51,367 in goodwill related to the MGT acquisition. On May 27, 2015, the Company entered into a collaborative drug development deal with IGX Bio and its GenePro®, a DNA-based immunotherapeutic that recently received FDA IND approval to enter into human trials. The companies intend to develop a joint protocol to demonstrate potential synergistic effects of their respective drug candidates in HIV, as well as potential new drug candidates. The collaboration between IGX Bio and the Company and will provide a scientific evaluation of GenePro® and CS-TATI-1 to demonstrate the enhanced potential of therapeutic vaccination and the anti-inflammatory effects of cannabinoids to deter disease progression in AIDS patients unable to control HIV replication. On May 7, 2015 the Company announced the acquisition of Equi-Pharm LLC, a USA manufacturer and distributor of specialty horse and pet grooming and topical applications. The acquisition incorporates an extensive expansion plan for Equi-Pharm including "Large Animal" such as horses, cattle, sheep and the like and "Small Animal" or "Pets" include cats, dogs, pet snakes and the like for medical and cosmetic products.
Basis of Presentation	B. Basis of Presentation These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S.dollars. The Company’s fiscal year end is December 31. Interim Financial Reporting While the information presented in the accompanying interim consolidated financial statements is unaudited, it includes all adjustments, which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in accordance with generally accepted accounting principles in the United States of America ("GAAP"). These interim financial statements follow the same accounting policies and methods of application as used in the December 31, 2014 audited financial statements of the Company. All adjustments are of a normal, recurring nature. Interim financial statements and the notes thereto do not contain all of the disclosures normally found in year-end audited financial statements and these Notes to Financial Statements are abbreviated and contain only certain disclosures related to the ninemonth periods ended September 30, 2015 and 2014. It is suggested that these interim financial statements be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2014 included in our Form 10-K, filed with the Securities Exchange Commission on April 21, 2015. Operating results for the ninemonths ended September 30, 2015 are not necessarily indicative of the results that can be expected for the year ending December 31, 2015. For other accounting policies please refer tothe Company’sForm 10-K with the SEC on file no. 000-28911 April 21, 2015. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2014, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. Earnings (Loss) Per Share (EPS) Basic earnings per common share are calculated by dividing net income or loss by the weighted average number of shares outstanding during the period. Diluted earnings per common share are calculated by adjusting outstanding shares, assuming conversion of all potentially dilutive stock options and warrants. The computation of diluted EPS does not assume conversion, exercise, or contingent issuance of shares that would have an anti-dilutive effect on earnings per common share. Anti-dilution results from an increase in earnings per share or reduction in loss per share from the inclusion of potentially dilutive shares in EPS calculations. Currently there are 1,700,000 stock options, which have been excluded from EPS that could potentially have a dilutive effect on EPS in the future. The table below sets forth the reconciliation for net loss and weighted average shares used for calculating basic and diluted earnings per share. Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Earnings (numerator) Net loss $ (3,767,628 ) $ (692,013 ) $ (14,203,584 ) $ (8,083,714 ) Stock dividends (473,527 ) — (473,527 ) — Net loss available to common shareholders $ (4,241,155 ) $ (692,013 ) $ (14,677,111 ) $ (8,083,714 ) Shares (denominator) Weighted average common shares outstanding 1,285,416,166 836,783,906 1,213,795,570 778,287,313 Earnings (loss) per share Basic and diluted $ (0.00 ) $ (0.00 ) $ (0.01 ) $ (0.01 )

Summary Of Significant Accoun18

Summary Of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2015
Summary Of Significant Accounting Policies Tables
Schedule of Reconciliation for Basic and Diluted Earnings Per Share	The table below sets forth the reconciliation for net loss and weighted average shares used for calculating basic and diluted earnings per share. Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Earnings (numerator) Net loss $ (3,767,628 ) $ (692,013 ) $ (14,203,584 ) $ (8,083,714 ) Stock dividends (473,527 ) — (473,527 ) — Net loss available to common shareholders $ (4,241,155 ) $ (692,013 ) $ (14,677,111 ) $ (8,083,714 ) Shares (denominator) Weighted average common shares outstanding 1,285,416,166 836,783,906 1,213,795,570 778,287,313 Earnings (loss) per share Basic and diluted $ (0.00 ) $ (0.00 ) $ (0.01 ) $ (0.01 )

Business Acquisitions (Tables)

Business Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2015
Business Acquisitions Tables
Schedule of Fair Value of the Consideration Transferred in the Acquisition	The following details the preliminary fair value of the consideration transferred to effect the acquisition of Equi-Pharm: Common stock of Cannabis Science, Inc. $ 305,000 Total fair value consideration $ 305,000
Schedule of Valuation of the Net Assets Acquired in the Acquisition	The following is a preliminary valuation of the net assets acquired by the Company in the acquisition, reconciled to the total fair value of the consideration transferred: Cash $ 6,493 Accounts receivable 285 Inventory 20,413 Accounts payable (413 ) Related party payable (1,919 ) Book value of net assets acquired as of May 7, 2015 24,859 Fair value adjustment to: Goodwill 280,141 Fair value of consideration transferred $ 305,000

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2015
Related Party Transactions Tables
Schedule of Stock Based Compensation with Related Party	For the nine months ended September 30, 2015, the following related party management fees and stock-based compensation was recorded: Related Party Position Amount Raymond Dabney 1 CEO and Director $ 586,201 Dr. Richard Ogden CSO 59,342 Robert Kane CFO and Director 642,511 Chad S. Johnson, Esq. COO, General Counsel, and Director 529,812 Mario Lap Director 88,659 $ 1,906,525 1

Equity Transactions (Tables)

Equity Transactions (Tables)	9 Months Ended
	Sep. 30, 2015
Equity Transactions Tables
Schedule of Stock Options Outstanding	A summary of the status of the Company’s option grants as of September 30, 2015 and the changes during the period then ended is presented below: Weighted-Average Shares Exercise Price Outstanding December 31, 2014 1,700,000 $ 0.41 Granted 61,500,000 0.01 Exercised (61,500,000 ) (0.01 ) Expired — Outstanding September 30, 2015 1,700,000 $ 0.41 Options exercisable at September 30, 2015 1,700,000 $ 0.41
Schedule of Weighted Average Fair Value Assumptions of Stock Option	The weighted average fair value at date of grant for options during nine months ended September 30, 2015 was estimated using the Black-Scholes option valuation model with the following: Average expected life in years 0 Average risk-free interest rate 2 % Average volatility 106 % Dividend yield 0 %

Subsequent Events (Tables)

Subsequent Events (Tables)	9 Months Ended
	Sep. 30, 2015
Subsequent Events Tables
Schedule of Common Shares Reconciliation Table	Common shares reconciliation table: Issued and outstanding as of September 30, 2015 1,287,155,296 Pending to be issued 91,500,000 Subsequent shares issued for services 8,000,000 Subsequent shares issued for debt settlement 30,000,000 Unissued and outstanding as of November 20, 2015 1,416,655,296

Summary Of Significant Accoun23

Summary Of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Earnings (numerator)
Net loss	$ (3,767,628)	$ (692,013)	$ (14,203,584)	$ (8,083,714)
Stock dividends	473,527		473,527
Net loss available to common shareholders	$ (4,241,155)	$ (692,013)	$ (14,677,111)	$ (8,083,714)
Shares (denominator)
Weighted average common shares outstanding	1,285,416,166	836,783,906	1,213,795,570	778,287,313
Earnings (loss) per share
Basic and diluted	$ 0	$ 0	$ (0.01)	$ (0.01)

Business Acquisitions (Schedule

Business Acquisitions (Schedule Of Fair Value Of The Consideration Transferred In The Acquisition) (Details) - Equi-Pharm, LLC [Member]	May. 07, 2015USD ($)
Restructuring Cost and Reserve [Line Items]
Common stock of Cannabis Science, Inc.	$ 305,000
Total fair value consideration	$ 305,000

Business Acquisitions (Schedu25

Business Acquisitions (Schedule of Valuation Of The Net Assets Acquired In The Acquisition) (Details) - Equi-Pharm, LLC [Member]	May. 07, 2015USD ($)
Restructuring Cost and Reserve [Line Items]
Cash	$ 6,493
Accounts receivable	285
Inventory	20,413
Accounts payable	413
Related party payable	1,919
Book value of net assets acquired as of May 7, 2015	24,859
Fair value adjustment to: Goodwill	280,141
Fair value of consideration transferred	$ 305,000

Related Party Transactions (Det

Related Party Transactions (Details)	9 Months Ended
	Sep. 30, 2015USD ($)
Related Party Transaction [Line Items]
Management fee and stock based compensation	$ 1,906,525
Raymond Dabney - CEO And Director [Member]
Related Party Transaction [Line Items]
Management fee and stock based compensation	586,201	[1]
Dr. Richard Ogden - CSO [Member]
Related Party Transaction [Line Items]
Management fee and stock based compensation	59,342
Robert Kane - CFO And Director [Member]
Related Party Transaction [Line Items]
Management fee and stock based compensation	642,511
Chad S. Johnson, Esq. - COO, General Counsel And Director [Member]
Related Party Transaction [Line Items]
Management fee and stock based compensation	529,812
Mario Lap - Director [Member]
Related Party Transaction [Line Items]
Management fee and stock based compensation	$ 88,659
[1]	Including compensation to entities beneficially owned/control by the related parties

Equity Transactions (Schedule O

Equity Transactions (Schedule Of Stock Options Outstanding) (Details)	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Shares
Outstanding December 31, 2014	1,700,000
Granted	61,500,000
Exercised	(61,500,000)
Expired
Outstanding September 30, 2015	1,700,000
Options exercisable at September 30, 2015	1,700,000
Weighted-Average Exercise Price
Outstanding December 31, 2014 | $ / shares	$ 0.41
Granted | $ / shares	0.01
Exercised | $ / shares	$ 0.01
Expired | $ / shares
Outstanding September 30, 2015 | $ / shares	$ 0.41
Options exercisable at September 30, 2015 | $ / shares	$ 0.41

Equity Transactions (Schedule28

Equity Transactions (Schedule Of Weighted Average Fair Value Assumptions Of Stock Options) (Details) - Stock Option [Member]	9 Months Ended
	Sep. 30, 2015
Fair value of Stock Options - Black Scholes Options Valuation Model
Average expected life in years	0 years
Average risk-free interest rate	2.00%
Average volatility	106.00%
Dividend yield	0.00%

Subsequent Events (Details)

Subsequent Events (Details) - shares	2 Months Ended	9 Months Ended
	Nov. 20, 2015	Sep. 30, 2015
Subsequent Event [Line Items]
Issued and outstanding as of September 30, 2015		1,032,123,906
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Issued and outstanding as of September 30, 2015	1,287,155,296
Pending to be issued	91,500,000
Subsequent shares issued for services	8,000,000
Subsequent shares issued for debt settlement	30,000,000
Unissued and outstanding as of November 20, 2015	1,416,655,296

Summary Of Significant Accoun30

Summary Of Significant Accounting Policies (Narrative) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Feb. 20, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Business acquisition recognized goodwill	$ 280,141
Emerging growth company description	The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2014, our last fiscal year.
Michigan Green Technologies, LLC [Member]
Business Acquisition [Line Items]
Business acquisition of additional interest acquired percentage		30.10%
Business acquisition ownership percentage		50.10%
Business acquisition recognized goodwill		$ 51,367

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - USD ($)	Mar. 27, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]
Advances from related parties		$ 756,993		$ 756,993		$ 203,892
Unrealized gain (loss) on marketable securities		(79,500)	$ (21,000)	(87,000)	$ (36,000)
Bogat Family Trust, Raymond Dabney - President/CEO As Trustee [Member] | Loans Payable [Member]
Related Party Transaction [Line Items]
Advances from related parties		191,344		$ 191,344		$ 191,344
Debt instrument description				The loan amounts due are non-interest bearing, unsecured and have no specified terms of repayment.		The loan amounts due are non-interest bearing, unsecured and have no specified terms of repayment.
Raymond Dabney - CEO And Director [Member] | Loans Payable [Member]
Related Party Transaction [Line Items]
Advances from related parties		0		$ 0			$ 6,166
Debt instrument description				The loan amounts due are non-interest bearing, unsecured and have no specified terms of repayment.			The loan amounts due are non-interest bearing, unsecured and have no specified terms of repayment.
MJR BV Owned And Controlled By Mario Lap, Director [Member] | Loans Payable [Member]
Related Party Transaction [Line Items]
Advances from related parties		$ 72,968		$ 72,968		$ 0
Debt instrument description				The loan is unsecured, non-interest bearing, and due upon demand.		The loan is unsecured, non-interest bearing, and due upon demand.
Robert Kane - CFO [Member]
Related Party Transaction [Line Items]
Debt instrument description	It was secured by a non-interest bearing promissory note due within 30 days of MGT liquidating shares in Cannabis Science, Inc. to repay the debt. The loan is unsecured, non-interest bearing, and due upon demand.
Loan from CFO to Michigan Green Technologies LLC	$ (52,500)
Endocan Corporation Related With Management - Director, CEO, CFO, COO [Member] | Equity Method Investment In Endocan Corporation (EC) [Member]
Related Party Transaction [Line Items]
Common stock invested		7,500,000		7,500,000
Fair market value of common stock held		$ 70,500		$ 70,500
Equity method investment ownership percentage		8.60%		8.60%
Share value per share		$ 0.01		$ 0.01
Unrealized gain (loss) on marketable securities				$ (87,000)	$ (36,000)

Notes Payable (Narrative) (Deta

Notes Payable (Narrative) (Details) - USD ($)	Aug. 20, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Short-term Debt [Line Items]
Notes payable to stockholders		$ 1,466,513		$ 1,581,486
Stock issued for debt settlement agreement, value		245,828	$ 29,500
Note Payable To Stockholder [Member]
Short-term Debt [Line Items]
Notes payable to stockholders		$ 1,466,513		$ 1,581,486
Debt instrument description		Notes payable are due to stockholders that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on May 30, 2012 through February 7, 2015. All Promissory notes are unsecured.		Notes payable are due to stockholders that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on May 30, 2012 through February 7, 2015. All Promissory notes are unsecured.
Note Payable To Stacey R. Lewis, Stockholder [Member] | Common Stock [Member]
Short-term Debt [Line Items]
Stock issued for debt settlement agreement, value	$ 25,000
Stock issued for debt settlement agreement, shares	25,000,000
Note Payable To Stacey R. Lewis, Stockholder [Member] | Stacey R. Lewis, Stockholder [Member]
Short-term Debt [Line Items]
Notes payable to stockholders		$ 130,855
Notes Payable [Member]
Short-term Debt [Line Items]
Promissory notes were in default		$ 1,340,156

Equity Transactions (Narrative)

Equity Transactions (Narrative) (Details) - USD ($)

Sep. 02, 2015

Jul. 16, 2015

May. 21, 2015

Apr. 29, 2015

Feb. 20, 2015

Jan. 15, 2015

Sep. 09, 2013

Aug. 30, 2013

Aug. 15, 2013

Jul. 23, 2013

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Pending shares to be issued

104,000,000

Stock issued for debt settlement agreement, value

$ 245,828

$ 29,500

Loss of settlement of debt

$ (770,000)

(4,488,076)

$ (2,116,500)

Proceeds from stockholder note payable

85,877

Fair value of dividends paid

$ 473,527

$ 473,527

Notes Payable From Intrinsic Capital Corp

Proceeds from stockholder note payable

$ 10,000

$ 1,250

$ 1,250

$ 18,328

Common Class A [Member]

Common stock voting rights

These shares have 10 votes per share.

Series A Preferred Stock [Member]

Preferred stock voting rights

These shares have full voting rights of 1,000 votes per share.

Common Stock [Member]

Common stock voting rights

These shares have full voting rights.

Pending shares to be issued

40,000,000

Increased in number of shares authorised

The Company increased the number of authorized shares of common stock from 1,500,000,000 to 3,000,000,000.

Fair value of dividends paid

$ 473,527

Common Stock [Member] | Stock Option [Member]

Shares approved for issuance at a later date

61,500,000

Common Stock [Member] | Notes Payable From Intrinsic Capital Corp

Stock issued for debt settlement agreement, shares

30,828,080

Stock issued for debt settlement agreement, value

$ 30,828

Loss of settlement of debt

$ (1,510,576)

Common Stock [Member] | Notes Payable to Intrinsic Capital Corp [Member]

Stock issued for debt settlement agreement, shares

40,000,000

Stock issued for debt settlement agreement, value

$ 40,000

Loss of settlement of debt

$ (1,360,000)

Common Stock [Member] | Settlement Of Debt [Member]

Stock issued for debt settlement agreement, value

$ 25,000

Loss of settlement of debt

$ (770,000)

Shares approved for issuance at a later date

25,000,000

Common Stock [Member] | Executive And Consultants [Member]

Shares issued for service during the period, shares

154,203,310

Common Stock [Member] | Consultant [Member]

Shares approved for issuance at a later date

17,500,000

Rule 144 Restricted Stock [Member]

Common stock sold, shares

10,000,000

Common stock sold, value

$ 250,000

Rule 144 Restricted Stock [Member] | Equi-Pharm, LLC [Member]

Stock issued for acquisition, shares

10,000,000

Rule 144 Restricted Stock [Member] | Notes Payable [Member] | Richard Cowan - Former Director And CFO [Member]

Stock issued for debt settlement agreement, shares

15,000,000

Stock issued for debt settlement agreement, value

$ 150,000

Fair market value of shares issued for debt settlement

997,500

Loss of settlement of debt

$ (847,500)

Rule 144 Restricted Stock [Member] | Joint Development Agreement With IGXBio Inc [Member]

Stock issued for Joint development agreement, shares

5,000,000

Deposits (Narrative) (Details)

Deposits (Narrative) (Details) - USD ($)	Nov. 20, 2014	Feb. 09, 2012
Rule 144 Restricted Stock [Member] | Acquisition of Apothecary as per license agreement [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Shares issued for acquisition of property, building and equipment	14,500,000
Shares issued for license agreement, value	$ 971,500
Licensing Agreements With Apothecary [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
License agreement terms and amendment	Apothecary failed to meet several contract provisions including investing $250,000 in R&D, setting up a laboratory facility, and reporting and remitting license fees owing to the Company. On November 20, 2014, the Company signed an amendment to the license agreement. Pursuant to the amendment, the Company is acquiring all property, building, and equipment of Apothecary	Apothecary will provide research and development facilities with full circle operations including a California laboratory facility for internal research and development, along with 16 unique genetic strains specifically generated and maintained by a cancer survivor who recognizes the importance of proper growth and breeding in addition to investing $250,000 in research and development in the first 24 months.

Equity Method Investee (Narrati

Equity Method Investee (Narrative) (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Nov. 05, 2014
Schedule of Equity Method Investments [Line Items]
Equity method investment in loan	$ 22,936	$ 50,000
Endocan Corporation Related With Management - Director, CEO, CFO, COO [Member] | Equity Method Investment In Endocan Corporation (EC) [Member]
Schedule of Equity Method Investments [Line Items]
Investment in marketable securities			$ 247,500
Equity method investment in loan			$ 85,681